Savara, Inc. is a high-risk, high-reward biotech focused solely on Molbreevi for treating aPAP. Click here to read why SVRA ...

If you purchased or acquired securities in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 ...

Levi & Korsinsky, LLP notifies investors in Savara Inc. (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors ...

LOS ANGELES, Sept. 22, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Savara Inc. ("Savara" or "the ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) investors concerning the Company’s ...

Savara (SVRA) “announced the acceptance of two abstracts for poster presentation and one abstract as an oral presentation at CHEST 2025 in ...

SVRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...

October 8, 2025) - If you suffered a loss on your Savara Inc. (NASDAQ: SVRA) investment and want to learn about a potential recovery under th ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who ...